businesspress24.com - Healthcare & Medical: Pressemitteilungen - Kategorie - Seite 5
 

Healthcare & Medical

Category / Healthcare & Medical


Cornerstone Robotics Launches First Clinical Evaluation of its Hong Kong-Developed Surgical Robotic System in UK

HONG KONG: HONG KONG, July 9, 2025 - (ACN Newswire) - Cornerstone Robotics (CSR) has announced the first formal clinical investigation of its Hong Kong-developed surgical robotic system at Portsmouth Hospitals U ...

Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation

HONG KONG: HONG KONG, July 4, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shang ...

Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

NEW YORK: Technology Co-Developed by the U.S. Department of Veteran Affairs and Emory University ...

NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances

HONG KONG: - Kidney Disease Treatment into a New Era of Precision Management ...

Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

HONG KONG: HONG KONG, Jun 9, 2025 - (ACN Newswire) - At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-gene ...

Know-where: Bone Structure Reveals Optimal Position for Screws in Fractures

: A new model from the Karl Landsteiner University of Health Sciences provides the basis for optimal positioning of orthopaedic screws. ...

First patient dosed in YK012 trial-the worlds first TCE therapy for primary membranous nephropathy

HONG KONG: Key Highlights - Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy - Globally, this is the first bispecific CD19-directed CD3 T cell engager immunothe ...

Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited

Singapore / Bangkok,: - Offer price of S$0.25 per share is at an attractive premium of 61.3% over the last traded price being 9 May 2025 and the 12-month volume-weighted average price - The Partial offer provides Cordlife ...

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Houston, TX,: - Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in th ...

Olympus Appoints New CEO

TOKYO: Names Bob White Representative Executive Officer, President, Chief Executive Officer and a new Director candidate ...


Page 5 von 304:  « ..  4 5 6  7  8  9  10  11  12  13  .. » 304





 

Who is online

All members: 10 677
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 135


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.